Connor, Clark & Lunn Investment Management (CC&L)
KNSA icon

Connor, Clark & Lunn Investment Management (CC&L)’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$36.6M Sell
572,598
-77,031
-12% -$4M 0.07% 248
2026
Q1 		$31.3M Sell
649,629
-89,697
-12% -$3.97M 0.07% 236
2025
Q4 		$30.5M Buy
739,326
+13,971
+2% +$560K 0.08% 209
2025
Q3 		$28.2M Buy
725,355
+101,666
+16% +$3.3M 0.09% 202
2025
Q2 		$17.3M Buy
623,689
+223,946
+56% +$5.7M 0.06% 271
2025
Q1 		$8.88M Buy
399,743
+92,797
+30% +$1.91M 0.04% 351
2024
Q4 		$6.07M Sell
306,946
-17,118
-5% -$391K 0.03% 437
2024
Q3 		$8.1M Buy
324,064
+92,985
+40% +$2.27M 0.04% 326
2024
Q2 		$4.31M Sell
231,079
-30,619
-12% -$574K 0.02% 457
2024
Q1 		$5.16M Buy
261,698
+2,415
+0.9% +$47.2K 0.02% 425
2023
Q4 		$4.55M Buy
259,283
+2,351
+0.9% +$38.6K 0.02% 450
2023
Q3 		$4.46M Buy
256,932
+96,288
+60% +$1.62M 0.02% 426
2023
Q2 		$2.26M Buy
160,644
+120,278
+298% +$1.61M 0.01% 579
2023
Q1 		$434K Buy
40,366
+18,007
+81% +$237K ﹤0.01% 923
2022
Q4 		$335K Buy
+22,359
New +$326K ﹤0.01% 962

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

Connor, Clark & Lunn Investment Management (CC&L)'s KNSA Position: Q2 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) reduced its Kiniksa Pharmaceuticals (KNSA) stake by 12% in Q2 2026, selling an estimated $4M and leaving 572,598 shares worth $36.6M. The position accounts for 0.07% of the portfolio, ranked #248.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in KNSA in Q4 2022 and has held it in 15 quarters since. 266 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

  • Connor, Clark & Lunn Investment Management (CC&L) held 572,598 shares of Kiniksa Pharmaceuticals worth $36.6M as of Q2 2026.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 77,031 Kiniksa Pharmaceuticals shares in Q2 2026, an estimated $4M.
  • Kiniksa Pharmaceuticals made up 0.07% of Connor, Clark & Lunn Investment Management (CC&L)'s portfolio in Q2 2026, its #248 holding.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Kiniksa Pharmaceuticals in Q4 2022 and has held it in 15 quarters since.
  • 266 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2026, filed 13 Aug 2026.